| dc.contributor.author | Carpintero Fernández, Paula | |
| dc.contributor.author | Varela Eirín, Marta | |
| dc.contributor.author | García Yuste, Alejandro | |
| dc.contributor.author | López Díaz, Iñaki | |
| dc.contributor.author | Caeiro Rey, José Ramón | |
| dc.contributor.author | Mayán Santos, María Dolores | |
| dc.date.accessioned | 2022-11-24T12:42:02Z | |
| dc.date.available | 2022-11-24T12:42:02Z | |
| dc.date.issued | 2022-03-15 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11940/17065 | |
| dc.description.abstract | Osteoarthritis (OA) is the most common joint disease. In the last years, the research community has focused on
understanding the molecular mechanisms that led to the pathogenesis of the disease, trying to identify different
molecular and clinical phenotypes along with the discovery of new therapeutic opportunities. Different types of
cell-to-cell communication mechanisms have been proposed to contribute to OA progression, including
mechanisms mediated by connexin43 (Cx43) channels or by small extracellular vesicles. Furthermore, changes
in the chondrocyte phenotype such as cellular senescence have been proposed as new contributors of the OA
progression, changing the paradigm of the disease. The use of different drugs able to restore chondrocyte
phenotype, to reduce cellular senescence and senescence-associated secretory phenotype components, and to
modulate ion channel activity or Cx43 appears to be promising therapeutic strategies for the different types of
OA. In this review, we aim to summarize the current knowledge in OA phenotypes related with aging and tissue
damage and the new therapeutic opportunities currently available. | es |
| dc.description.sponsorship | European Regional Development Fund, ‘‘A way of making Europe’’ from the European Union (to María D. Mayán): grant PI19/ 00145 | es |
| dc.description.sponsorship | Xunta de Galicia (IN607B2020/12) (to María D. Mayán) | es |
| dc.description.sponsorship | H2020, Future and Emerging Technologies (Grant 858014 ‘‘PANACHE’’) to María D. Mayán | es |
| dc.description.sponsorship | EuroNAnoMed | es |
| dc.description.sponsorship | Joint Transnational Call for proposals for European Innovative Research & Trchnological Development Projects in Nanomedicine, ISCIII (AC21_2/00026) to María D. Mayán. | es |
| dc.description.sponsorship | Instituto de Salud Carlos III (ISCIII) | es |
| dc.language.iso | eng | es |
| dc.subject.mesh | Therapeutics | * |
| dc.subject.mesh | Cartilage, Articular | * |
| dc.subject.mesh | Connexin 43 | * |
| dc.subject.mesh | Chondrocytes | * |
| dc.title | Osteoarthritis: Mechanistic Insights, Senescence, and Novel Therapeutic Opportunities | es |
| dc.type | Artigo | es |
| dc.rights.holder | El editor | es |
| dc.identifier.doi | https://doi.org/10.1089/bioe.2021.0039 | |
| dc.issue.number | 1 | es |
| dc.journal.title | Bioelectricity | es |
| dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC) | es |
| dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Traumatoloxía | es |
| dc.page.initial | 39 | es |
| dc.page.final | 47 | es |
| dc.relation.projectID | Xunta de Galicia/IN607B2020/10 | es |
| dc.relation.publisherversion | https://www.liebertpub.com/doi/10.1089/bioe.2021.0039 | es |
| dc.rights.accessRights | embargoedAccess | es |
| dc.subject.decs | conexina 43 | * |
| dc.subject.decs | terapéutica | * |
| dc.subject.decs | cartílago articular | * |
| dc.subject.decs | condrocitos | * |
| dc.subject.keyword | INIBIC | es |
| dc.subject.keyword | CHUS | es |
| dc.typefides | Artigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis) | es |
| dc.typesophos | Artículo Original | es |
| dc.volume.number | 4 | es |